Idorsia (IDIA.SW)

Executive Summary

Idorsia is a Swiss biopharmaceutical company focused on innovative small-molecule therapeutics. Its marketed product, daridorexant (Quviviq), addresses insomnia and provides a commercial foundation. The pipeline includes late-stage assets: clazosentan (Phase 3 for delayed cerebral ischemia after subarachnoid hemorrhage) and lucerastat (Phase 3 for Fabry disease). Despite strong science, Idorsia faces financial challenges with ongoing cash burn and reliance on partnerships. Key near-term catalysts involve clazosentan pivotal data and potential label expansion for daridorexant, which could drive significant value inflection.

Upcoming Catalysts (preview)

• Q3 2026Clazosentan PHAST Phase 3 top-line results65% success
• Q4 2026Daridorexant label expansion (e.g., sleep apnea) regulatory submission50% success
• Q3 2026Strategic partnership or licensing deal to reduce cash burn70% success